Bloomsbury Genetic Therapies Limited ("Bloomsbury"), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, recently announced its launch with a £5 million seed financing led by UCL Technology Fund.
International legal practice Osborne Clarke advised UCL Technology Fund on its investment in Bloomsbury, which was founded as a spinout from UCL and supported by UCL Business.
The investment will enable Bloomsbury to progress its innovative approach which is designed to optimise therapeutic efficacy and safety, enable high manufacturability, accelerate development timelines and maximise regulatory success to create a pipeline of highly differentiated first or best-in-class programmes.
Bloomsbury's lead programmes are liver and CNS targeted gene therapies, which are underpinned by world-leading gene therapy and rare disease expertise from the company's academic founders.
Osborne Clarke's team was led by Partner Justin Starling and included Senior Associate Magnus Williams. Additional support was provided by Associate Amy Moylett (employment), Associate Director Jon Round and Associate Lucy Price (commercial).
Osborne Clarke’s Corporate team is considered a go-to practice for many companies in the life sciences and healthcare sector. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.